

Paul K Marcom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/144681/publications.pdf>

Version: 2024-02-01

31
papers

2,745
citations

394421

19
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

4367
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 5305-5313.	1.6	600
2	Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. <i>Molecular Cancer Research</i> , 2011, 9, 997-1007.	3.4	586
3	Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 2502-2512.	1.6	338
4	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	1.6	276
5	Surgery of the primary tumor does not improve survival in stage IV breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 459-465.	2.5	101
6	Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2198-2206.	1.6	99
7	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
8	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914.	0.5	74
9	Breast Cancer Patients'™ Treatment Expectations after Exposure to the Decision Aid Program Adjuvant Online: The Influence of Numeracy. <i>Medical Decision Making</i> , 2010, 30, 464-473.	2.4	68
10	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	7.1	68
11	Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. <i>Supportive Care in Cancer</i> , 2014, 22, 2851-2859.	2.2	55
12	Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. <i>Breast</i> , 2015, 24, 630-636.	2.2	52
13	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	7.0	50
14	Retinoic Acid Receptor- β Promoter Methylation in Random Periareolar Fine Needle Aspiration. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 790-798.	2.5	45
15	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 347-356.	2.5	38
16	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	10.9	38
17	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.0	31
18	Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300. <i>Microscopy Research and Technique</i> , 2002, 59, 23-40.	2.2	25

#	ARTICLE	IF	CITATIONS
19	Hypermethylation of the Breast Cancer-associated Gene 1 Promoter Does Not Predict Cytologic Atypia or Correlate with Surrogate End Points of Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 50-56.	2.5	23
20	A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 289-297.	2.4	21
21	Symptom Communication in Breast Cancer: Relationships of Holding Back and Self-Efficacy for Communication to Symptoms and Adjustment. <i>Journal of Psychosocial Oncology</i> , 2013, 31, 698-711.	1.2	19
22	Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 317-321.	1.0	18
23	Benefit or Bias? The Role of Surgery to Remove the Primary Tumor in Patients with Metastatic Breast Cancer. <i>Annals of Surgery</i> , 2008, 247, 739-740.	4.2	15
24	Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 635-43.	2.5	10
25	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
26	Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool. <i>Journal of Geriatric Oncology</i> , 2019, 10, 968-972.	1.0	6
27	Optimizing the Quality of Breast Cancer Biomarker Use at Duke Cancer Institute. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, S-21-S-24.	4.9	3
28	TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).. <i>Journal of Clinical Oncology</i> , 2013, 31, 515-515.	1.6	2
29	Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. <i>Journal of Biophotonics</i> , 2020, 13, e201960235.	2.3	0
30	Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6503-6503.	1.6	0
31	Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.. <i>Journal of Clinical Oncology</i> , 2016, 34, 602-602.	1.6	0